Alps Advisors Inc Morpho Sys Ag Transaction History

Alps Advisors Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$9.08 - $12.45 $1.5 Million - $2.06 Million	-165,509 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.76 - $19.51 $83,319 - $138,228	-7,085 Reduced 4.11%	165,509 $1.95 Million
Q2 2021 Aug 11, 2021	SELL	$18.95 - $23.95 $1.24 Million - $1.57 Million	-65,423 Reduced 27.49%	172,594 $3.32 Million
Q1 2021 May 07, 2021	BUY	$21.56 - $30.66 $4,743 - $6,745	220 Added 0.09%	238,017 $5.19 Million
Q4 2020 Feb 03, 2021	BUY	$24.81 - $30.33 $1.68 Million - $2.06 Million	67,910 Added 39.97%	237,797 $6.74 Million
Q3 2020 Nov 04, 2020	SELL	$30.28 - $35.72 $289,870 - $341,947	-9,573 Reduced 5.33%	169,887 $5.33 Million
Q2 2020 Aug 05, 2020	SELL	$24.08 - $33.35 $1.23 Million - $1.71 Million	-51,270 Reduced 22.22%	179,460 $5.68 Million
Q1 2020 May 06, 2020	SELL	$18.86 - $37.36 $482,023 - $954,846	-25,558 Reduced 9.97%	230,730 $5.67 Million
Q4 2019 Feb 07, 2020	BUY	$26.07 - $36.32 $66,895 - $93,197	2,566 Added 1.01%	256,288 $9.14 Million
Q3 2019 Nov 04, 2019	SELL	$24.18 - $31.58 $282,857 - $369,422	-11,698 Reduced 4.41%	253,722 $6.97 Million
Q2 2019 Aug 07, 2019	BUY	$23.24 - $26.76 $6.17 Million - $7.1 Million	265,420 New	265,420 $6.41 Million

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.